clinical trial · NCT04076059
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.·phase3·active not recruiting·n = 180
Metastatic Hormone Sensitive Prostate CancerEnzalutamidePlaceboAndrogen deprivation therapy (ADT)
brief summary
The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.
started
Sep 11, 2019
primary completion
Nov 18, 2022
completion
Dec 31, 2028
last updated
Oct 20, 2026
official title
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol